WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

The 2026 WorkBoat Diesel Directory is here. See engine specs and manufacturer listings for the U.S. commercial fleet. → Download Free

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

85.76 +2.17 (+2.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Halozyme Therapeutics Q2 Earnings Call Highlights ↗
Halozyme Therapeutics (NASDAQ:HALO) reported record second-quarter revenue and raised its full-year outlook, citing growth in royalty income from its ENHANZE drug-delivery platform, contributions from... 
Via MarketBeat
Topics Earnings
News headline image
Halozyme Therapeutics (NASDAQ:HALO) Beats Expectations in Strong Q2 CY2026, Guides for Strong Full-Year Sales
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales... 
Via StockStory
News headline image
What To Expect From Halozyme Therapeutics’s (HALO) Q2 Earnings
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) will be announcing earnings results this Thursday after the bell. Here’s what to ... 
Via StockStory
News headline image
3 Growth Stocks Set to Flourish
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil... 
Via StockStory
Halozyme Therapeutics (NASDAQ:HALO): A Value Stock Profile Offering Strong Profitability and a Low Forward P/E ↗
Via Chartmill
Halozyme Therapeutics Inc (NASDAQ:HALO): A Deep Value Play Combining Strong Profitability with an Attractive 14.35 P/E ↗
Via Chartmill
Halozyme Therapeutics (NASDAQ:HALO) Surges After Q1 Beat, Launches $1 Billion Buyback ↗
Via Chartmill
News headline image
1 Cash-Producing Stock on Our Watchlist and 2 We Ignore
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
Topics Energy
News headline image
1 Value Stock Worth Investigating and 2 Facing Headwinds
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t... 
Via StockStory
News headline image
2 Reasons to Like HALO and 1 to Stay Skeptical
Halozyme Therapeutics trades at $78.57 and has moved in lockstep with the market. Its shares have returned 8.5% over the last six months while the S&P 500 ha... 
Via StockStory
Topics Stocks
News headline image
1 Surging Stock for Long-Term Investors and 2 We Brush Off
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements... 
Via StockStory
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Value Investment Case ↗
Via Chartmill
Halozyme Therapeutics Inc (NASDAQ:HALO) Reports Mixed Q4 2025 Results with Revenue Beat and Unexpected Loss ↗
Via Chartmill
News headline image
2 Profitable Stocks Worth Your Attention and 1 We Question
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
Topics Credit Cards
News headline image
Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today
What Happened? Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 5.2% in the afternoon session after an analyst re... 
Via StockStory
Topics Economy
News headline image
Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions
Halozyme Therapeutics’ first quarter results for 2026 were met with a positive market response, underpinned by substantial royalty revenue growth and the exp... 
Via StockStory
Topics Earnings
News headline image
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi... 
Via StockStory
Topics Economy
News headline image
Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a... 
Via StockStory
Topics Artificial Intelligence
News headline image
HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up ... 
Via StockStory
News headline image
Halozyme (HALO) Q1 2026 Earnings Transcript ↗
Halozyme (HALO) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Halozyme Therapeutics Q1 Earnings Call Highlights ↗
Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced... 
Via MarketBeat
Topics Earnings
News headline image
Halozyme Therapeutics’s (NASDAQ:HALO) Q1 CY2026 Sales Top Estimates
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up ... 
Via StockStory
News headline image
Halozyme Therapeutics Earnings: What To Look For From HALO
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) will be announcing earnings results this Monday after market close. Here’s what t... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 of Wall Street’s Favorite Stock with Exciting Potential and 2 That Underwhelm
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
Via StockStory
News headline image
3 Cash-Producing Stocks with Exciting Potential
Free cash flow is one of the most reliable indicators of financial durability. These businesses not only generate cash but reinvest intelligently to sustain ... 
Via StockStory
News headline image
2 Small-Cap Stocks with Solid Fundamentals and 1 We Ignore
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th... 
Via StockStory
News headline image
1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th... 
Via StockStory
News headline image
Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Haloz... 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Reasons to Like HALO (and 1 Not So Much)
Since August 2025, Halozyme Therapeutics has been in a holding pattern, posting a small loss of 2.1% while floating around $70.71. The stock also fell short of the S&P 500’s 6.2% gain during that... 
Via StockStory
Topics Stocks
News headline image
Halozyme (HALO) Q4 2025 Earnings Call Transcript ↗
Halozyme (HALO) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2026 Diversified Communications. All rights reserved.